SEC62 and neoplasm: When screening publicly available DNA sequencing data from over 72,000 cancer patients with 55 different tumor entities (cBio Portal for cancer genomics; https://www.cbioportal.org accessed on 21 April 2021) SEC62 gene alterations are reported for 2595 patients and represent gene amplifications in the majority of cases (Figure 10a).